ULTIMOVACS ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.98 NOK | +0.29% |
|
-11.65% | -94.32% |
| Apr. 17 | Ultimovacs to Reduce 40% of Workforce Amid Operational Adjustments | MT |
| Apr. 17 | Transcript : Ultimovacs ASA - Special Call |
Presenter SpeechCarlos de Sousa (Executives)Good morning, everybody, and welcome to our busine...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacsâ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
6.98
NOK
Average target price
6.5
NOK
Spread / Average Target
-6.88%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -94.32% | 21.69M | |
| +0.35% | 42.19B | |
| +44.30% | 40.15B | |
| -6.20% | 28.31B | |
| +6.01% | 24.63B | |
| -22.74% | 18.2B | |
| +28.25% | 12.01B | |
| -2.49% | 11.76B | |
| +15.07% | 10.4B | |
| -5.11% | 9.94B |
- Stock Market
- Equities
- ULTI Stock
- News Ultimovacs ASA
- Transcript : Ultimovacs ASA - Special Call
